TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A retrospective analysis of University of Florida health records found that glucosamine use was associated with a 25% higher likelihood that mild cognitive impairment would progress to dementia. The researchers also reported supporting laboratory and mouse-model work, but the human record analysis cannot show that glucosamine caused the outcomes, and clinical trials are needed.
Researchers at the University of Florida reported that people with mild cognitive impairment who used glucosamine were more likely to progress to dementia in a retrospective health-record analysis. The study, published in Nature Metabolism, also included experiments examining a possible metabolic explanation, but its human findings show an association and do not establish that the supplement causes dementia to progress.
The team used artificial intelligence to analyze deidentified UF Health records collected from 2012 to 2024. It focused on patients diagnosed with mild cognitive impairment, or MCI, and people with Alzheimer’s disease or related dementias, grouped in the report as ADRD. MCI involves measurable difficulties with memory or thinking beyond what is expected with normal aging, but those difficulties do not necessarily substantially disrupt everyday life.
About 8% of patients in each group reported taking glucosamine: 2,750 people in the MCI group and 1,896 in the ADRD group. After adjusting for age, sex and demographic factors, glucosamine use was associated with a 25% higher likelihood of MCI progressing to dementia. Among people already diagnosed with ADRD, use was associated with a 25% higher mortality risk during the study’s defined observation period. Researchers did not observe that mortality association among patients with MCI.
The report also describes work with human brain tissue and mouse models of Alzheimer’s disease. The researchers examined a pathway involved in attaching sugar structures to proteins, a normal cellular process that they said showed signs of excessive activity in Alzheimer’s disease. The supplied report does not provide the detailed results of the mouse experiments, so their size and specific outcomes cannot be assessed here.
A Common Supplement Raises a Clinical Question
Glucosamine is widely sold over the counter and is commonly used, particularly by older adults, for joint discomfort and joint health. An association with faster progression from MCI to dementia could matter to people taking the supplement and to clinicians reviewing what their patients use. The study does not show that stopping glucosamine would slow dementia, or that taking it caused the observed outcomes.
The mortality finding concerns a different group and outcome: patients who already had ADRD. Researchers reported an association with higher mortality in that group, but not in the MCI group. These results warrant careful follow-up because they involve two distinct patient populations and cannot by themselves establish how glucosamine affects an individual’s risk.
The proposed metabolic pathway also adds a line of investigation alongside research on amyloid plaques and tau tangles, two well-known features of Alzheimer’s disease. The team suggests that metabolism may contribute to disease progression. That is a research interpretation supported by the study’s combined analyses and experiments, not proof that this pathway explains the human health-record association.
How Researchers Examined Glucosamine
Glucosamine is a naturally occurring, sugar-related molecule. The report says it can cross the blood-brain barrier and enter biochemical pathways involved in building complex sugar structures and attaching them to proteins. Commercial supplements can be made from materials including shellfish shells or corn.
The researchers used a spatial technology developed in senior author Ramon Sun’s laboratory to examine large numbers of molecules in tissue. They then investigated glucosamine in experiments involving human brain tissue and mouse models. The report proposes that the effects of the molecule could vary with the biological environment, meaning a healthy brain and a brain affected by Alzheimer’s may respond differently.
Alzheimer’s research has often focused on amyloid beta deposits, known as plaques, and abnormal tau proteins, known as tangles. The study’s authors argue that altered metabolism deserves attention as another possible contributor. The record analysis and laboratory work offer a basis for further research, while leaving the question of cause and effect unresolved.
“A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse.”
— Ramon Sun, senior author and director of the University of Florida’s Center for Advanced Spatial Biomolecule Research
Cause, Risk, and Patient Advice Remain Unclear
The retrospective analysis cannot establish whether glucosamine caused MCI to progress or whether other differences between supplement users and nonusers contributed to the association. Adjustments for age, sex and demographics do not rule out all possible confounding factors. The report does not specify the absolute number of MCI patients who progressed, the length of follow-up for each patient, or the baseline risk used to interpret the 25% figure.
The findings also do not establish whether risk varies by dose, duration of use, supplement formulation, or the reason a person takes glucosamine. The report says effects may depend on the brain’s biological state, but it does not identify which patients, if any, face a particular risk. It gives no clinical-trial results showing that changing glucosamine use affects dementia outcomes.
The available source describes mouse-model research but cuts off before reporting its specific findings. The extent to which those experiments support the proposed mechanism is consequently unclear from the material provided. The research team says the findings need testing in a human clinical trial.
Human Trials Needed to Test the Link
The next key step is research designed to test whether glucosamine use contributes to dementia progression, including a human clinical trial as the researchers say is needed. Further studies would also need to clarify the timing and size of any risk, account for other differences between supplement users, and assess whether results vary across patient groups or patterns of use.
Until such evidence is available, the study does not supply a basis for predicting an individual’s outcome from supplement use. People concerned about glucosamine or cognitive symptoms can discuss their circumstances and supplement use with a qualified health professional.
Key Questions
Does this study prove glucosamine causes dementia to progress?
No. The human finding came from a retrospective analysis of health records and shows an association. It cannot establish that glucosamine caused MCI to progress to dementia.
What did the study find about mild cognitive impairment?
After adjustments for age, sex and demographics, glucosamine use was associated with a 25% higher likelihood that MCI would progress to dementia. The report does not provide the absolute progression rate or the baseline risk behind that figure.
Did researchers find a link to mortality?
Among people already diagnosed with ADRD, glucosamine use was associated with a 25% higher mortality risk during the defined study period. The researchers did not observe this association in the MCI group. The finding does not prove the supplement caused deaths.
Should people stop taking glucosamine?
This study did not test whether stopping glucosamine changes dementia risk or progression. People with questions about supplements or cognitive symptoms can discuss them with a qualified health professional.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
